Daxxify in Lansing, MI
Daxxify (daxibotulinumtoxinA-lanm) is the first FDA-approved neuromodulator formulated with a proprietary stabilizing peptide excipient rather than human serum albumin — making it the longest-lasting injectable wrinkle relaxer currently available in the United States. For patients in the greater Lansing area who are tired of quarterly appointments, it represents a meaningful shift: clinical trial data show that more than 50% of patients maintained no or mild frown lines for six months or longer after a single treatment. At Maison Zolara, located at 4820 W Saginaw Hwy in west Lansing, our licensed registered nurse (RN) clinicians offer Daxxify as part of a comprehensive, MD-supervised neuromodulator menu — with pricing starting From $15/unit (Maison Circle members From $13/unit).
- ✓Daxxify (daxibotulinumtoxinA-lanm)
- ✓FDA-cleared technology
- ✓All skin types
- ✓MD-supervised
- ✓RN-performed
- ✓Free consultation
- ✓Package pricing available
How It Works
Daxxify works by the same fundamental mechanism as all botulinum toxin type A neuromodulators: it temporarily blocks acetylcholine release at the neuromuscular junction, preventing the targeted muscle from contracting and allowing overlying skin to smooth. What sets it apart is how long it sustains that effect.
The key innovation is a proprietary stabilizing excipient peptide called RTP004, which replaces the human serum albumin used in older formulations. This peptide-based stabilizer is believed to contribute to the extended duration of action observed in clinical trials — a median of approximately 24 weeks (six months) across the SAKURA 1 and SAKURA 2 phase 3 studies. Because it contains no human- or animal-derived proteins, Daxxify is also notable as a vegan-friendly neuromodulator option.
Onset is typically rapid. According to patient diary data from the SAKURA trials, many patients reported seeing measurable improvement within two days of treatment, with peak effect generally achieved within one to two weeks.
Clinical bottom line: According to pooled data from the SAKURA 1 and SAKURA 2 phase 3 trials published in the Journal of the American Academy of Dermatology, daxibotulinumtoxinA maintained none or mild glabellar line severity for a median of 24 weeks — roughly twice the duration of standard neuromodulators. ↗
What It Treats
Daxxify is FDA-approved for the temporary improvement of moderate to severe glabellar lines (the vertical frown lines between the brows) in adults. At Maison Zolara, our licensed RN clinicians also discuss its off-label applications during your consultation, which may include:
Glabellar Lines
The "11s" between the brows — the FDA-approved indication for Daxxify. Clinical trials demonstrated 74% of patients achieved a two-grade or greater improvement at week 4 per both physician and patient assessment.
Forehead Lines
Horizontal lines across the forehead caused by frontalis muscle activity. Neuromodulator treatment softens these lines while preserving natural expression.
Crow's Feet
Lateral orbital lines from orbicularis oculi contraction. A common off-label application discussed during your personalized consultation.
Brow Lift
Strategic placement along the brow can create a subtle lift effect, opening the eye area without surgery — a popular option for patients in Okemos and East Lansing who want a refreshed look.
About Daxxify
Daxxify (daxibotulinumtoxinA-lanm) received FDA approval on September 7, 2022, making it the first new neuromodulator approved for glabellar lines in the United States in over a decade. It is manufactured by Revance Therapeutics, Inc.
Peptide-Stabilized Formula
Unlike all other FDA-approved neuromodulators, Daxxify uses the proprietary RTP004 peptide excipient instead of human serum albumin or animal-derived proteins. This formulation is free of human and animal components — a meaningful distinction for patients with specific ethical or dietary preferences.
Extended Duration
The SAKURA phase 3 program enrolled more than 2,700 subjects across approximately 4,200 treatments. The median duration of none or mild glabellar line severity was 24 weeks, with some patients maintaining results at nine months. According to data cited by the FDA, more than 50% of patients had no or minor frown lines at six months.
Rapid Onset
Patient diary data from the SAKURA trials indicate that many subjects reported seeing measurable improvement within two days of injection — a faster perceived onset than is typically reported with onabotulinumtoxinA (Botox), where initial results are generally noted at three to seven days.
Vegan-Friendly
Because RTP004 is a synthetic peptide and the formulation contains no human serum albumin or animal-derived stabilizers, Daxxify is considered the first vegan-friendly neuromodulator option available in the United States.
Safety & Risks
Daxxify has a well-characterized safety profile established across the SAKURA phase 3 clinical program. As with all botulinum toxin products, it carries an FDA Boxed Warning regarding the potential for toxin spread beyond the injection site.
FDA Boxed Warning: Botulinum toxin products, including Daxxify, may spread from the injection site and cause symptoms of botulism, including difficulty swallowing, speaking, or breathing, which can be life-threatening. These symptoms have been reported hours to weeks after injection. The risk is greatest in patients treated for conditions other than cosmetic facial lines. Seek immediate medical attention if these symptoms occur. Daxxify is not interchangeable with other botulinum toxin products.
In the SAKURA glabellar line trials, the most common adverse reactions (≥1%) included:
- Headache — reported in approximately 6% of subjects; generally mild and transient
- Eyelid ptosis (drooping) — reported in approximately 2% of subjects; temporary and resolves as the toxin wears off
- Facial paresis — reported in approximately 1% of subjects
- Injection site reactions — erythema, bruising, and tenderness, typically resolving within 24–72 hours
Serious adverse events were rare. The overall safety profile was comparable to other approved neuromodulators. All treatments at Maison Zolara are performed by our licensed RN clinicians under the clinical oversight of our on-staff Medical Director, and a thorough medical history review is completed prior to every treatment.
Contraindications include: known hypersensitivity to any botulinum toxin product or formulation components; infection at the proposed injection site; and pregnancy or breastfeeding. Patients with neuromuscular disorders (e.g., myasthenia gravis, Lambert-Eaton syndrome) should discuss their history with a qualified provider before treatment.
Alternatives
Daxxify is one of several FDA-approved neuromodulators available at Maison Zolara. The right choice depends on your treatment goals, lifestyle, and how frequently you prefer to schedule appointments. The table below summarizes the key differences.
When comparing options, the primary clinical differentiator for Daxxify is duration. Patients in DeWitt, Mason, and surrounding communities who prefer fewer annual appointments often find the six-month profile appealing. Patients who prefer to start with a shorter-acting product to gauge their response may prefer to begin with one of the alternatives below.
| Feature | Daxxify | Botox | Dysport | Xeomin |
|---|---|---|---|---|
| Generic name | daxibotulinumtoxinA-lanm | onabotulinumtoxinA | abobotulinumtoxinA | incobotulinumtoxinA |
| FDA approval (glabellar) | 2022 | 2002 | 2009 | 2011 |
| Typical duration | ~6 months | ~3–4 months | ~3–4 months | ~3–4 months |
| Stabilizer | Synthetic peptide (RTP004) | Human serum albumin | Human serum albumin | None (naked toxin) |
| Vegan-friendly | Yes | No | No | No |
| Onset | ~2 days (reported) | ~3–7 days | ~2–5 days | ~3–7 days |
Botox, Dysport, and Xeomin are shorter-acting neuromodulator alternatives, each covered on their own dedicated pages at Maison Zolara. Our licensed RN clinicians can help you compare options during a complimentary consultation.
"Will I Look Frozen?"
The concern about looking "frozen" or expressionless is one of the most common questions our team hears from patients considering any neuromodulator — and it is worth addressing directly.
A frozen appearance is the result of over-treatment or imprecise placement, not an inherent property of the product. Daxxify, like any neuromodulator, relaxes the targeted muscle; it does not eliminate all movement. When dosed conservatively and placed precisely by a skilled injector, the result is a softening of dynamic lines while preserving natural facial expression.
Because Daxxify's effects last longer than standard toxins, precise dosing at the outset is especially important. Our licensed RN clinicians take a conservative, anatomy-first approach: we start with the appropriate dose for your muscle mass and facial anatomy, assess your response, and adjust at follow-up if needed. The goal is always a refreshed, natural result — not a static one.
The peptide-stabilized formulation does not change the mechanism of muscle relaxation; it extends the duration of the same targeted effect. Patients who have had natural-looking results with other neuromodulators can expect the same quality of outcome with Daxxify, with the added benefit of fewer annual treatments.
What to Expect
Before Your Treatment
Your journey begins with a complimentary consultation with one of our licensed RN clinicians. We review your medical history, discuss your aesthetic goals, assess your facial anatomy and muscle activity, and confirm that Daxxify is appropriate for you. We will explain the dosing approach, expected duration, and what to do if you have any questions after your appointment. Patients from Holt, Grand Ledge, Williamston, and St. Johns are welcome — our west Lansing location on W Saginaw Hwy is easily accessible from across the mid-Michigan region.
During Treatment
The appointment itself is brief — typically 15 to 30 minutes. After cleansing the treatment area, your RN clinician will administer a series of small injections using a fine-gauge needle. Most patients describe the sensation as a mild pinch. No anesthesia is required, though a topical numbing cream is available on request. The number of injection points and units used will be determined based on your anatomy and goals, confirmed during your consultation.
After Treatment
You can return to most normal activities immediately. Avoid lying flat, vigorous exercise, and rubbing the treated area for four hours post-treatment. Avoid alcohol and anti-inflammatory medications for 24 hours to minimize bruising risk. Initial results are typically visible within two to three days, with peak effect at one to two weeks. Your RN clinician will schedule a follow-up to assess your response and address any questions.
Aftercare
Proper aftercare helps protect your results and minimize the risk of side effects. The following guidelines apply to the first 24–48 hours after treatment.
Pricing
Daxxify at Maison Zolara is priced per unit, reflecting the precision dosing approach used by our licensed RN clinicians.
- Standard pricing: From $15/unit
- Maison Circle member pricing: From $13/unit
- Final unit count and total pricing are confirmed at your consultation, based on your anatomy and treatment goals
According to pooled phase 3 data published in the Journal of the American Academy of Dermatology, the median duration of effect for daxibotulinumtoxinA was 24 weeks — meaning patients may require only two treatments per year compared to three or four with standard neuromodulators. ↗
Because Daxxify typically lasts approximately twice as long as standard neuromodulators, the cost-per-month comparison is often favorable for patients who currently maintain quarterly appointments. Our team is happy to walk through this math during your consultation.
Maison Circle members receive member pricing on Daxxify and can track their treatment journey in the Zolara Care app (available on the App Store).
Am I a Good Candidate?
Daxxify is appropriate for most healthy adults who want to reduce the appearance of moderate to severe glabellar lines and prefer a longer-lasting result. It is a particularly strong fit for patients who:
FAQ
Related Treatments
Botox in Lansing, MI
OnabotulinumtoxinA — the most widely studied neuromodulator, with a three-to-four-month duration. A strong option for patients new to injectables or those who prefer more frequent dosing adjustments.
Xeomin in Lansing, MI
IncobotulinumtoxinA — a "naked toxin" formulation with no complexing proteins. Covered on its own dedicated page at Maison Zolara.
Dermal Fillers in Lansing, MI
RHA Collection hyaluronic acid fillers for volume restoration, lip enhancement, and facial contouring — often combined with neuromodulators for a comprehensive result.
RF Microneedling in Lansing, MI
Candela Matrix RF microneedling for collagen remodeling, skin texture, and acne scars — a complementary treatment to neuromodulators for overall skin quality.
Masseter Botox & TMJ in Lansing, MI
Neuromodulator treatment for jaw slimming and TMJ-related bruxism — a specialized application discussed during your consultation.
Injectables Overview
Browse the full injectable menu at Maison Zolara, including neuromodulators, dermal fillers, Sculptra, and biostimulators.
Serving the Greater Lansing Area
Maison Zolara is located at 4820 W Saginaw Hwy in west Lansing, MI 48917 — conveniently situated on W Saginaw Hwy with easy access from across the mid-Michigan region. We serve patients from Lansing, East Lansing, Okemos, Holt, DeWitt, Grand Ledge, Charlotte, Mason, St. Johns, Williamston, and surrounding communities within a 30-mile radius.
Our clinic hours are 9:00 AM – 7:00 PM Monday through Friday and 9:00 AM – 5:00 PM on Saturday. Free consultations are available — book online or call us to schedule.
Clinical References
Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020;82(4):838–845. https://pubmed.ncbi.nlm.nih.gov/31609882/
U.S. Food and Drug Administration. Daxxify (daxibotulinumtoxinA-lanm) — FDA Approval History. First approved September 7, 2022. https://www.drugs.com/history/daxxify.html
Drugs.com. Daxxify (daxibotulinumtoxinA-lanm): Package Insert / Prescribing Information. https://www.drugs.com/pro/daxxify.html
Skin Therapy Letter. DaxibotulinumtoxinA-lanm (Daxxify™): A Comprehensive Overview. https://www.skintherapyletter.com/cosmetic-dermatology/daxibotulinumtoxina-lanm-daxxify/
Page Disclaimer: The information on this page is provided for educational purposes only and does not constitute medical advice. Clinical references are sourced from peer-reviewed research and named institutions as cited below. Individual results vary. Consult a qualified healthcare provider before beginning any treatment.
The Medical Director provides clinical oversight of treatments performed at this practice. The Medical Director does not author, review, or endorse website content.
Daxxify® is a registered trademark of Revance Therapeutics, Inc.